




Evidence-based approach to management of glaucoma during **pregnancy**

Thasarat Sutabutr Vajaranant, MD
Associate Professor
Director, Glaucoma Service

I do not have financial interests

Research Support

- K23EY022949 (NEI)
- K12HD055892 (NICHD and ORWH)
- American Glaucoma Society
 - Young Clinician-Scientist Award
 - MAPS
 - Mid-Career Physician-Scientist Award
- Komarek-Hyde-McQueen Foundation Glaucoma Research Fund created in Honor of Dr. Mark W. Lunde
- Bausch & Lomb, Aerie, and Allergan



29-year-old African American woman had advanced visual field loss from traumatic glaucoma/angle recession.

She undergoing trabeculectomy with mitomycin C 6 weeks ago presented with uncontrolled intraocular pressure on maximal medical therapy.

Her pressure was 57 mmHg, including oral acetazolamide.



What if she told you she is now **pregnant**

- Does pregnancy make it better or worse?
- Medical and surgical considerations during pregnancy
 - How about mitomycin use during the first trimester?
- Special considerations during labor and lactation


Glaucoma during pregnancy

- 1) Incidence of glaucoma during the childbearing age (age < 40) < 0.5%
 - Increased maternal age
 - By 90% in women aged 35-39
 - By 50% in women aged 45-54
- 2) No guidelines
- 3) According to a survey in the UK, only 1/3 of consultants had experience with the treatment of glaucoma during pregnancy

Questionnaire survey in the UK


26% (of 282) had experience with the treatment

If concerning progression



Questionnaire survey in the UK

26% (of 282) had experience with the treatment



Glaucoma during pregnancy

Good news

- IOP decreases by 10% throughout pregnancy, which persists several months after delivery
- The majority 2/3 are stable

Not so good news

- About 1/3 are concerning
 - Progression based on visual field (18%)
 - IOP elevation (18%)

Why does intraocular pressure decrease during pregnancy?

UNCHANGED
Aqueous
Production

INCREASED
Trabecular and
Uveoscleral
Outflow

DECREASED
Episcleral
Venous
Pressure



10 to 20% IOP reduction


Related to beta HCG and Progesterone

Dinn RB, Harris A et al. OB & GYN survey 2003
Weinreb AJO 1988 Sethi 2016



The Course of Glaucoma during Pregnancy

28 eyes of 15 pregnant women



Timing

First trimester: concerning teratogenic effects

- Organogenesis

Second and third trimesters

- Organ development and maturation

Third trimester

- Premature labor and well-being of the newborn

Factors that increase risk of toxicity

Maternal Factor

- Increased blood volume and AFP interfere drug binding

Fetal Factors

- Smaller blood volume
- Immature liver and kidney metabolism
- Prolonged exposure due to re-circulation through amniotic fluid



Approach

Goal: Temporizing measures to minimize progression

- **Assess urgency of treatment**

- Review pre-natal records
 - Severity of glaucoma
 - Set goal of treatment, including target pressure
-
- Familiarity with drug classification
 - Consultations
 - Multidisciplinary approach
 - Glaucoma specialist
 - OB especially in a high-risk pregnancy
 - Discuss risks and benefits of treatment with the patient

Treatment Options

- **Observation**
- **Medical treatment**
 - Topical
 - Oral: Avoid!!!
- **Laser**
 - ALT
 - Diode cyclophotocoagulation
- **Surgical**
 - Trabeculectomy
 - Tube/Shunt



Drug Classification

- **Class A:**
Safety established in human studies
- **Class B:**
Presumed safety based on animal studies
- **Class C: Uncertain**
No human studies
Animal studies showed adverse effects
- **Class D: Unsafe**
Evidence of risk in certain clinical circumstance
- **Class X: Highly unsafe**

Anti-glaucomatous medications

- **Class A: NONE**
- **Class B:**
 - Brimonidine
 - Dipivefrin
- **Class C:**
 - Beta blocker
 - CAI
 - Prostaglandin analog
 - Epinephrine and apraclonidine
 - Parasympatomimetics
- **Class D: Unsafe**
- **Class X: Highly unsafe**
 - Cholinesterase inhibitor ***

Postpone only
in the first trimester



Medical treatment during pregnancy

	Pregnancy
1st Line	Brimonidine (Class B)
2nd Line	Beta blocker Class C: 0.25% q am Most commonly used by ophthalmologists and used to treat HTN
3rd Line	CAI (topical) Class C
Alternative	Pilocarpine Discontinue near term
	Prostaglandin

Medical treatment during lactation

	Pregnancy	Lactation
1st Line	Brimonidine (Class B)	Discontinue prior to delivery
2nd Line	Beta blocker Class C: 0.25% q am Most commonly used by ophthalmologists and used to treat HTN	May discontinue during nursing in small infants due to high concentration in breastmilk
3rd Line	CAI (topical) Class C	CAI (topical and oral)
Alternative	Pilocarpine Discontinue near term	Pilocarpine
	Prostaglandin	Prostaglandin

Lactation

- Most drugs present in the maternal circulation are excreted into milk
 - The maximum amount of drug in milk seldom exceed **1% to 2%** of the administered maternal dose
- Evidence of secreted drug in breast milk
 - Timolol:
 - 6-time higher drug concentration in breast milk at 1 1 1/2 hours
 - About 1/80 of the cardiac-effect dose
 - **Caution in small infants with hepatic or renal impairment**



Lactation

Drug level in breast milk often highest 30-120 minutes after the dose

Recommendations

Timolol and acetazolamide

- Approved by **American Academy of Pediatrics**
- **Timing**– administer right after nursing

Methods to reduce systemic absorption

- Punctal occlusion
- Lowest concentration
- Gel form— sustained release
- Timing
 - Discontinue near term or prior to delivery
 - Administer drops immediately after nursing
 - Drug level in breast milk highest during 30-120 minutes

LASER: The least possible risk to fetus

Recommended as a temporizing measure

Reported safety with ALT and diode cyclophotocoagulation

Surgical options

- **Filtering surgery**
 - Trabeculectomy – **antifibrotic agents (Class D)**
 - Glaucoma drainage device
- **Risk of anesthesia**
 - Not recommended during the first trimester
 - Safety reported with uses of retrobulbar block with lidocaine
 - Consider topical anesthesia

Preparation for labor

- The effects of labor on IOP
 - No changes in IOP and MOPP during the second and third stage of labor in young healthy women with no glaucoma
 - Excluded women who later needed C-section
 - Unknown in women with glaucoma

Recommendations:

- Recommendation on a choice of delivery is inconsistent
 - 2% of C-section reports from Poland were due to eye related conditions (including glaucoma)

29-year-old African American woman had advanced visual field loss from traumatic glaucoma/angle recession. She undergoing trabeculectomy with mitomycin C 6 weeks ago presented with uncontrolled intraocular pressure on maximal medical therapy. Tmax 57 including oral acetazolamide.

Summary

- Glaucoma in pregnancy although uncommon, can be challenging in management
 - Most cases do well!
- Multidisciplinary approach and familiarity with treatment options is crucial
- Consider temporizing measures to minimize maternal risk of progression as well as fetal risk of adverse effects from medications



Thank you for your attention

thasarat@uic.edu



Illinois Eye
AND EAR INFIRMARY



THE UNIVERSITY OF ILLINOIS
COLLEGE OF MEDICINE
CHICAGO PEORIA ROCKFORD URBANA